Cambridge Healthtech Institute’s Inaugural

Digital Health: Pharmaceutical Executive Summit
( デジタルヘルス:製薬業界エグゼクティブサミット )

医薬品開発、診断、医療の分野における臨床的有用性と新たな応用分野

2019年6月18日~19日


Digital Health is promising to revolutionize healthcare delivery, optimize personalized and precision medicine, and offer new tools for drug and diagnostic development. The applications of biosensors, mobile devices and wearables, Internet of Things, mobile health platforms, artificial intelligence, and digital biomarkers are quickly expanding into all areas of patient monitoring and disease management, point-of-care diagnostics, and digital endpoints in clinical trials. Cambridge Healthtech Institute’s Inaugural Digital Health: Pharmaceutical Executive Summit will bring together leading experts and thought leaders in digital health to discuss the latest technologies and implementation of digital tools into drug development, diagnostics and healthcare.

Final Agenda

Stay on to attend Wednesday, June 19 - Thursday, June 20

Digital Biomarkers: Biosensors, Wearables, and mHealth

6月18日(火)

7:00 am Registration Open and Morning Coffee

デジタル治療

8:00 Chairperson’s Remarks

Joris Van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research


8:10 KEYNOTE PRESENTATION: Digital Therapeutics in Pharma

Joris Van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research

Digital Therapeutics represent a novel treatment modality, where high-quality, clinically validated software applications are used for the prevention, management or treatment of disease. We will review some of our key experiences from our partnership with Pear Therapeutics that was announced in March 2018: What is the unmet need that can be addressed? What are potential synergies between digital- and pharmacotherapies? How can a large pharma organization best adopt digital therapeutics?

8:40 The Rise of Digital Therapeutics as Companions to Existing and Future Therapies

Pierre Leurent, CEO, Voluntis

Digital therapeutics (DTx) represent a new class of solutions that have the potential to improve patients’ treatment experience, by enhancing the efficacy and/or safety of medications. Case studies will illustrate how these solutions are currently developed and commercialized in different therapeutic areas. Future development scenarios will be explored, including the advent of drug/DTx combination therapies.

9:10 Transforming Care Models and Business Models with Digital Medicine

David J. O’Reilly, Chief Platform Officer, Proteus Digital Health

The FDA has approved the world’s first NDA for a medicine including an ingestible sensor and an associated digital care management offering. The product and the expanding digital medicine field it represents also signals the emergence of a new business model for the pharmaceutical industry, one based on the integration of medications with software, analytics and services as well as one directly linked to patient-specific outcomes as the measure of pharmaceutical value.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

10:25 Digital Health: Design for the Behavior You Would Like to See

Christian Theil Lundgaard, PhD, Director, Digital Health Partnerships & Commercial Strategy, Novo Nordisk

Digital Health will impact and improve the real-world health outcomes experienced by people with diabetes using innovative medications from Novo Nordisk to treat type 1 and type 2 diabetes. The Digital Health initiative in Novo Nordisk takes point of departure in the connected injection device, with an aim of designing solutions that allow people with diabetes to spend less time thinking about their disease and more time living their life.

10:55 PANEL DISCUSSION: Future of Digital Therapeutics

Moderator: Joris Van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research

Panelists: Speakers of the day

Discussion topics include:

  • What are the emerging business models for digital therapeutics?
  • How are big pharma impacted by digital therapeutics?
  • What are the unmet technology needs?

11:25 Sponsored Presentation (Opportunity Available)

11:55 Transition to Lunch

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

患者中心の考え方に基づく臨床試験のためのモバイルヘルスとデジタルツール

1:05 Chairperson’s Remarks

Mohanad Fors, MBA, Co-Founder, Global Head of Biome - The Digital Innovation Lab by Novartis

1:10 Virtual Clinical Trials, Empowering Patients and Create 20k Trial

Mohanad Fors, MBA, Co-Founder, Global Head of Biome - The Digital Innovation Lab by Novartis

This talk will share the new landscape of the digital health ecosystem and the important role of technology to disrupt how pharma works, touching one of the key critical topics in pharma which is clinical trials and empowering the patients as part of our role in supporting the ecosystem and the patients.

1:40 KEYNOTE PRESENTATION: Re-Imagining the Clinical Trial Ecosystem from the Protocol to Clinical Execution

Mohammed Ali, Global Head, Digital Development, Global Clinical Operations, Boehringer Ingelheim Pharmaceuticals

The clinical trial ecosystem over the past 3-4 years has been challenged by many new paradigms which leverage technology and innovation to rethink how we conduct studies. There have been many discussions around patient centricity and engagement which is essential in ensuring studies focus on the delivery of key therapies for those that need it most. But there is also still great opportunity left at the process level within the other two stakeholders – sponsors and sites – to ensure new ways of working also to permeate these important partners.

2:10 Sponsored Presentation (Opportunity Available)

2:25 Refreshment Break in the Exhibit Hall with Poster Viewing

3:10 Making Trials More Attractive, Inclusive and Manageable with Innovative Use of Connected Devices: Case Studies and Lessons Learned from a Big Pharma Company

Bert Hartog, PhD, Senior Director, Clinical Innovation, Janssen Pharmaceutica N.V.

Clinical trials are notoriously difficult to execute. Finding the right people to participate and motivating them to stay in the trial are significant challenges for study sponsors and sites. Innovative use of connected devices can be a gamechanger, reducing the trial burden, integrating trials into people’s daily lives and collecting more granular data. Use cases will be presented to show how to make this happen in a big pharma enviroment.

3:40 Utilizing Everyday Technologies to Accelerate Patient Recruitment and Engagement

Magdalena Schoeneich, Head, Takeda Digital Accelerator, R&D, Takeda

Join us to learn about a unique partnership between Takeda, MIT Media Lab and IDEO: three different companies and scientists that came together to understand how AI and gamification could be used to increase patient engagement and retention in clinical trials. We will discuss: 1) designing and validating a mobile game to increase long-term adherence to self-reporting data; 2) building a unique patient-centric engine to help patients understand the language of clinical programs as well as lowering the burden of trial participation.

4:10 Transition to Keynote


4:20 PLENARY KEYNOTE SESSION

5:20 Welcome Reception in the Exhibit Hall with Poster Viewing

6:35 Find Your Table, Meet Your Moderator

6:40 Breakout Discussion Groups

7:30 Close of Day

6月19日(水)

7:00 am Registration Open and Morning Coffee

大手製薬会社におけるモバイルヘルス

8:00 Chairperson’s Remarks

Tomasz Adamusiak, MD, PhD, Director Medical Informatics Lead, Digital Medicine & Translational Imaging, Pfizer

8:05 Digital Health Opportunities 2025

Raj Pallapothu, mHealth Global Lead, Bayer

8:35 Breakthrough Digital – Making a Positive Impact on Millions of Patients

Adrian Chernoff, MBA, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson

It’s not every day a breakthrough product is created. From idea to market, we will cover the R&D journey in delivering digital transformation at scale at Johnson & Johnson. The result is the #1 diabetes app in the U.S. and Canada with over one million downloads. We will cover the multi-faceted dynamics of developing a breakthrough digital at scale inclusive of customer experience, putting the patient at the center, big data, agile vs. waterfall, IoT, cloud, data privacy, intelligent medical devices and remote patient monitoring.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

ビッグデータ:デジタルヘルスの分野における人工知能 (AI) と機械学習

10:20 Building a Digital Health Data Pipeline in the Cloud

Tomasz Adamusiak, MD, PhD, Director Medical Informatics Lead, Digital Medicine & Translational Imaging, Pfizer

The mission of the Digital Medicine group and the Pfizer Innovation Research (PfIRe) Lab is to solve key business problems using dynamical measures and advanced STEM platforms. Our goal is to utilize digital remote monitoring of patients’ symptoms to develop and validate novel clinical endpoints for disease diagnosis and health state assessment. This presentation will explore the unique challenges of digital biomarkers from a data engineering and knowledge management perspective.

10:50 Humanizing Care through AI

Kamal Jethwani, MD, MPH, Senior Director, Pivot Labs, Partners HealthCare; Assistant Professor, Harvard Medical School

Health systems and healthcare industries are eagerly diving into AI and machine learning technologies, allocating significant resources toward validating and refining predictive algorithms for a range of applications, including diagnostic tools and aids to clinical decision making. However, we need to understand the human users of these algorithms, and how their clinical workflows, decisions, and relationships with patients will be affected, and how best to position AI for success in the delivery of care.

11:20 Precision Healthcare through Multi-Scale Biomedical Data Integration

Jessilyn Pearl Dunn, PhD, Assistant Professor, Biomedical Engineering and Biostatistics & Bioinformatics, Duke University

Recent technological advancements make it possible to closely and continuously monitor individuals on multiple scales in real time while also incorporating genetic, environmental, and lifestyle information. We are collecting and using this multi-scale biomedical data to gain a more precise understanding of health and disease at molecular and physiological levels and developing actionable, predictive health models for improving cardiometabolic outcomes.

11:50 Transition to Lunch

12:00 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Transition to Plenary


12:50 PLENARY KEYNOTE SESSION

2:20 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing

3:05 Close of Conference

Stay on to attend Wednesday, June 19 - Thursday, June 20

Digital Biomarkers: Biosensors, Wearables, and mHealth

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新履歴
2019/05/23
アジェンダ・スポンサー更新
2019/05/13
アジェンダ・講演者更新
2019/04/22
講演者更新
2019/04/10
スポンサー更新
2019/03/27
講演者・スポンサー更新
2019/02/20
アジェンダ・講演者・スポンサー更新



メール配信サービス